Drugs / Tobemstomig
Tobemstomig
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05908786 | Dec 2023 → Aug 2025 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT05116202 | Feb 2022 → Sep 2023 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04140500 | Nov 2019 → Jun 2027 expected | esophageal squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05852691 | Jul 2023 → Oct 2026 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05805501 | Apr 2023 → Oct 2026 expected | renal cell carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05645692 | Apr 2023 → Dec 2026 expected | urothelial carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05775289 | Mar 2023 → Jun 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05419388 | Aug 2022 → May 2024 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04785820 | Jun 2021 → Jan 2025 | esophageal squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tobemstomig | “tobemstomig (anti-PD-1/anti-LAG-3 bispecific antibody; n = 40)” PMID 40993242 ↗ Sep 2025 |
| Known as | ANTI-PD1/ANTI-LAG3 BISPECIFIC ANTIBODY RO7247669 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗ |
| Known as | PD1-LAG3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗ |
| Known as | PD1-LAG3 (RO-7247669) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗ |
| Known as | PD1-LAG3 BSAB (RO-7247669) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗ |
| Known as | RG-6139 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗ |
| Known as | RO7247669 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04140500 ↗ |
| Action | Inhibit | “an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody” NCT04140500 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315001 ↗ |
| Route | Intravenous | “intravenous (IV) RO7247669” NCT04140500 ↗ |